Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

作者： Sundar,Jagannath ^[1] ; Nedra,Joseph ^[2] ; Concetta,Crivera ^[2] ; Akshay,Kharat ^[3] ; Carolyn C,Jackson ^[4] ; Satish,Valluri ^[5] ; Patricia,Cost ^[5] ; Hilary,Phelps ^[5] ; Rafal,Slowik ^[5] ; Timothy,Klein ^[6] ; Lee,Smolen ^[6] ; Xueting,Yu ^[6] ; Adam D,Cohen ^[7]

作者单位： Icahn School of Medicine at Mount Sinai, New York, NY, USA. ^[1] Janssen Scientific Affairs, LLC, Horsham, PA, USA. ^[2] Janssen Scientific Affairs, LLC, Horsham, PA, USA. AKharat2@its.jnj.com. ^[3] Janssen R&D, Raritan, NJ, USA. ^[4] Janssen Global Services, LLC, Raritan, NJ, USA. ^[5] Medical Decision Modeling Inc., Indianapolis, IN, USA. ^[6] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. ^[7]

关键词 Chimeric antigen receptor T-cell (CAR-T) therapy Ciltacabtagene autoleucel (cilta-cel)Relapsed/refractory multiple myeloma (RRMM)

DOI 10.1007/s40487-023-00228-5

PMID 37014590

发布时间 2023-06-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Oncology and therapy

2023年11卷2期

263-275页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.

Oncology and therapy

相似文献

Oncology and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.

Oncology and therapy

相似文献

Oncology and therapy

相关期刊

检索历史清除